Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography

Saravanan, R; Somanathan, T.; Gavaskar, D.; V, Sriraman.; Tamilvanan, M.

doi:10.52711/0974-360x.2022.00356

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-based nanoparticles are a promising delivery system for many treatments 1 . It is a submicron colloidal dispersion of drug particles that is mostly utilized to get beyond the constraints of colloidal carriers like emulsions and liposomes since it has a great releasing profile and outstanding physical stability 1,2 . One of the cutting-edge technologies, lipid-based drug delivery systems (LBDDS), aims to solve the problems of poor solubility and bioavailability.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Dolutegravir, an integrase strand transfer inhibitor (INSTI), is a BCS class II, poorly soluble antiretroviral medication that has been licenced by the FDA for the treatment of HIV infections. DTG has a number of drawbacks, including limited oral bioavailability (16%), hepatotoxicity, and instability in an acidic environment. Due to the medication's limited solubility, 84% of the dose is eliminated from the body after oral administration in an unaltered state. Lipidbased nanoparticles have been chosen for the current research study as a viable drug delivery technology to help with the aforementioned challenges. Melt emulsification sonication procedure was used with CAPMUL MCM EP, Glyceryl monostearate, TWEEN 80, SPAN 80, and other ingredients, a total of six formulations were created. The formulations' particle size, polydispersity index, zeta potential, drug concentration, drug entrapment effectiveness, in-vitro release, and other factors were assessed. The prepared formulations demonstrated zeta potential of -11.78 to-26.6, in-vitro drug release of between 62 and 80.32 percent, and particle sizes varying from 155 to 205 nm. The best formulation, according to the early trial, was F2. Particle size Y1 and in-vitro drug release Y2 were two dependent variables, and F2 was fitted to a 2 2 factorial design with two independent factors, concentration of span 80 -X1 and sonication duration -X2. 4 runs were compared, and code R2 was determined to be the most optimal formulation. The improved dolutegravir-loaded Nano formulation offers an adequate release and may be appropriate for large-scale manufacturing with improved therapeutic outcome and patient compliance.

show abstract

Section: Introductionmentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

show abstract

Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography

Cited by 1 publication

References 6 publications

Untitled

Untitled

Contact Info

Product

Resources

About